Share on LinkedInShare on LinkedIn

ARTICLE · 22 JANUARY 2024

Market Intelligence Thought Leadership Award Winner

PAAB Revisions: Real-World Evidence In Advertising

This article provides an update to our series on the use of real-world data ("RWD") and real-world evidence ("RWE"). The Pharmaceutical Advertising Advisory Board (PAAB) has published revisions...

CanadaLitigation, Mediation & Arbitration

This article provides an update to our series on the use of real-world data ("RWD") and real-world evidence ("RWE"). The Pharmaceutical Advertising Advisory Board (PAAB) has published revisions to the Code of Advertising Acceptance (the "Code") on the use of RWE in advertising directed to healthcare professionals ("HCPs"). The revised Code also includes guardrails related to use of subjective endpoints from open-label randomized controlled trials and data from clinical trials in other jurisdictions where the drug formulation differs from the Canadian formulation only in respect of inactive ingredients. PAAB has announced that the revised Code will take effect on February 1, 2024.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from